Ronald D. Seidel III, Ph.D.
Executive Vice President, Head of Research and Development
Ron Seidel is co-founder of Cue Biopharma and co-inventor of its technologies. Dr. Seidel has oversight of daily Company operations, including integrating R&D and intellectual property (IP) development strategy with operational capabilities and scientific direction. Specifically, he leverages expertise in molecular engineering towards the generation of new high value assets. Previously Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. The function of the MTDF was to leverage high throughput technologies for the development, analysis and production of protein-based therapeutics. Additionally, through the MTDF, Dr. Seidel was the Associate Director of Eukaryotic Protein Production at the Northeast BioDefense Center (NBC). He has also served as consultant to industry in biologics and protein production. Dr. Seidel holds a B.S. and Ph.D. in Biochemistry from the University of Georgia. He did his post-doctoral work at the New York Structural Biology Center.
Steven Almo, Ph.D.
Co-Founder and Chair of SAB
Steven Almo is the Chairman of the Department of Biochemistry at Albert Einstein College of Medicine, where he is Professor of Biochemistry and of Physiology & Biophysics. Dr. Almo holds the Wollowick Family Foundation Chair in Immunology and is Director of Einstein’s Macromolecular Therapeutics Development Facility, a resource dedicated to the development and optimization of protein-based therapeutics. Dr. Almo is recognized for his broad contributions to structural biology and has published more than 300 papers. His laboratory has played key roles in the development and implementation of high-throughput approaches for protein production, structure determination and functional annotation. Dr. Almo received his Ph.D. in Biophysics from Harvard University, while working with Greg Petsko in the Chemistry Department at MIT, and is best known for his high resolution structural and biochemical characterization of the CTLA-4 and PD-1 immune checkpoint proteins and their respective ligands. The strategy for clonal-specific T cell modulation, which underlies Cue Biopharma’s therapeutic discovery pipeline, was developed in Dr. Almo’s laboratory.
Rodolfo J. Chaparro, Ph.D.
Rodolfo Chaparro is co-founder of Cue Biopharma and co-inventor of its technologies. He currently serves as Senior Advisor to Cue Biopharma. From the Company’s formation in 2015 through February 2020, Dr. Chaparro was responsible for the Company’s immuno-oncology and autoimmunity research programs as well as its preclinical and early clinical development. Prior to Cue Biopharma, Dr. Chaparro was a research faculty member in the Department of Biochemistry at the Albert Einstein College of Medicine in New York. Dr. Chaparro possesses research expertise in molecular immunology and immunotherapeutics development and was Head of Immunology within its Macromolecular Therapeutics Development Facility (MTDF). Dr. Chaparro holds a B.S. in Biology from the University of California at Irvine and a Ph.D. in immunology from Stanford University.